Literature DB >> 21958503

Delivering affordable cancer care in high-income countries.

Richard Sullivan1, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, Mark De Ridder, Susan A McCloskey, Dirk Verellen, Terence Roberts, Guy Storme, Rodney J Hicks, Peter J Ell, Bradford R Hirsch, David P Carbone, Kevin A Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy G Brinker, David Meltzer, David Kerr, Matti Aapro.   

Abstract

The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21958503     DOI: 10.1016/S1470-2045(11)70141-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  185 in total

Review 1.  Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.

Authors:  David R Yates; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-11-23       Impact factor: 4.226

2.  Nuclear medicine, scientific publishing and the era of cost containment.

Authors:  Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12       Impact factor: 9.236

3.  Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?

Authors:  Richard L Theriault
Journal:  Oncologist       Date:  2012-02-02

4.  Targeted therapies: Manufacturer sponsorship bias in economic analyses matters.

Authors:  David Kerr; Ahmed Elzawawy
Journal:  Nat Rev Clin Oncol       Date:  2012-05-01       Impact factor: 66.675

Review 5.  Review and uses of stereotactic body radiation therapy for oligometastases.

Authors:  Filippo Alongi; Stefano Arcangeli; Andrea Riccardo Filippi; Umberto Ricardi; Marta Scorsetti
Journal:  Oncologist       Date:  2012-06-20

6.  Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis.

Authors:  Te-Chun Hsia; Chih-Yen Tu; Hsin-Yuan Fang; Ji-An Liang; Chia-Chin Li; Chun-Ru Chien
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

Review 7.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

8.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

Review 9.  The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.

Authors:  Nicolas Iragorri; Claire de Oliveira; Natalie Fitzgerald; Beverley Essue
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

10.  Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.

Authors:  Rezwanul Hasan Rana; Fariha Alam; Khorshed Alam; Jeff Gow
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.